Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Reviewing Autolus Therapeutics (NASDAQ:AUTL) & AIM ImmunoTech (NASDAQ:AIM)
06:52am, Saturday, 25'th Jan 2020
Autolus Therapeutics (NASDAQ:AUTL) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of t
Why Autolus Therapeutics Shares Are Plunging Today
04:44pm, Thursday, 23'rd Jan 2020
Investors are reacting negatively to the biotech's public stock offering.
Arix Bioscience Plc - Autolus announces pricing of public offering - Vox Markets
07:00am, Thursday, 23'rd Jan 2020
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014. LONDON, 23 January 2020: Arix Bioscience plc, a global venture capital company focused o
Autolus Announces Pricing of Public Offering
02:41am, Thursday, 23'rd Jan 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in th
Autolus Announces Pricing of Public Offering
02:41am, Thursday, 23'rd Jan 2020
LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...
Autolus Announces Proposed Public Offering in the United States
09:41pm, Wednesday, 22'nd Jan 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an offering of up to 7,250,000
Autolus Announces Proposed Public Offering in the United States
09:41pm, Wednesday, 22'nd Jan 2020
LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...
Autolus Therapeutics (NASDAQ:AUTL) Downgraded to Hold at Zacks Investment Research
08:12am, Wednesday, 15'th Jan 2020
Autolus Therapeutics (NASDAQ:AUTL) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. According
Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference
12:00pm, Monday, 13'th Jan 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, is presenting at the 38th Annual J.P. Morgan Healthcare Conference o
Autolus Therapeutics: Just Another CAR T Company
09:24pm, Friday, 10'th Jan 2020
Autolus Therapeutics is developing a series of CAR Ts candidates across several cancer indications. Its products are designed to overcome some of the limitation
Is Autolus Therapeutics (NASDAQ:AUTL) In A Good Position To Invest In Growth?
11:15am, Friday, 10'th Jan 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Wall Street Recommends Catching These 2 Falling Knives
04:48pm, Wednesday, 08'th Jan 2020
These companies face no bankruptcy risk, although the sharp market devaluation could make us believe the opposite Continue reading...
Autolus Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
11:30am, Friday, 20'th Dec 2019
LONDON, Dec. 20, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
12:59pm, Wednesday, 18'th Dec 2019
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
